Study: J&J COVID-19 Vaccine 72% Effective in U.S.

The video discusses the Johnson & Johnson COVID-19 vaccine, highlighting its 66% efficacy in preventing moderate to severe disease 28 days post-vaccination. It emphasizes the maturation of immune response over time, with no hospitalizations or deaths among vaccinated individuals. The vaccine's efficacy varies by region, being 72% in the US, 66% in Latin America, and 57% in South Africa. Despite lower efficacy compared to other vaccines, it remains a crucial tool in combating the pandemic. J&J plans to seek FDA emergency approval, with the US having an agreement to purchase 100 million doses.

What was the effectiveness of the Johnson & Johnson vaccine in preventing moderate to severe COVID-19 disease 28 days after vaccination?

• 80%

• 75%

• 66%

• 50%

How does the Johnson & Johnson vaccine deliver the coronavirus spike protein into cells?

• By direct injection of the spike protein

• Via a bacterial vector

• Using a modified common cold virus

• Through a live coronavirus

What level of protection did the Johnson & Johnson vaccine provide against hospitalization and death in the trials?

• 100%

• 50%

• 75%

• 90%

In which region did the Johnson & Johnson vaccine show the lowest effectiveness?

• South Africa

• Latin America

• Europe

• United States

What is the US's agreement with Johnson & Johnson regarding vaccine doses?

• To buy 50 million doses

• To buy 100 million doses

• To buy 200 million doses

• To buy 300 million doses